TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21349111
Drug: comb-NBUVB (NBUVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: comb-NBUVB (NBUVB therapy with daily application of antimicrobial gel)
Study: 21349111
Drug: mono-NBUVB (NBUVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: mono-NBUVB (NBUVB therapy without antimicrobial gel)
Study: 21349111
Drug: NBUVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBUVB treatment (both comb-NBUVB and mono-NBUVB)
Study: 12504395
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (2 mg, daily for 2 years)
Study: 8558626
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (300 mg per kg of body mass)
Study: 8558626
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mg sodium chloride per kg of body mass and 200 mg calcium carbonate per kg of body mass)
Study: 637277
Drug: Caudad injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudad injection via a 22 gauge Whitacre needle
Study: 637277
Drug: Cephalad or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalad or lateral injection via a 22 gauge Whitacre needle
Study: 637277
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose caudally directed injections
Study: 29264882
Drug: Removable appliance
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable appliance therapy with electronic sensors for cooperation assessment
Study: 23501141
Drug: Internal motivations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal motivations for seeking treatment
Study: 23501141
Drug: General motivations
Approvals — FDA: no, EMA: no, PMDA: no
Description: General motivations for seeking treatment
Study: 16404515
Drug: High-dose intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intracoronary brachytherapy (24 Gy)
Study: 31863206
Drug: Pregabalin (PG)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PG) 150 mg per os, 2 doses preoperatively
Study: 26284299
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (expected to eat less than 300 g of fish and mussels per week)
Study: 23026173
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine plus 3 mg fentanyl
Study: 23026173
Drug: 0.1% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% levobupivacaine plus 3 mg fentanyl
Study: 23026173
Drug: 0.05% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% levobupivacaine plus 3 mg fentanyl
Study: 19740915
Drug: CyA (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA (AUC 1700‐2000 ng/ml) + PSL (0.8 mg/kg/day)
Study: 19740915
Drug: PSL alone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSL alone (1.0 mg/kg/day)
Study: 18801159
Drug: Standard arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm: total dose 6.0 Gy in single fractions of 1.0 Gy applied twice a week
Study: 18801159
Drug: Experimental arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm: total dose 0.6 Gy in single fractions of 0.1 Gy applied twice a week (acting as a placebo)
Study: 16052085
Drug: CD4-based co-trimoxazole
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4-based co-trimoxazole initiation (< 500, < 200, < 50 x 10(6) CD4 cells/l)
Study: 10509848
Drug: Dorzolamide hydrochloride
Normalized name: Dorzolamide Hydrochloride
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dorzolamide hydrochloride ophthalmic solution 2% TID
Study: 8750152
Drug: IFN-alpha monotherapy
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha monotherapy
Study: 819597
Drug: Idoxuridine (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxuridine (given hourly by day and at 2-hr intervals by night for three days)
Study: 819597
Drug: Human interferon
Normalized name: Human interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human interferon (1.1 X 10(7) international units/ml, applied daily)
Study: 819597
Drug: Human interferon
Normalized name: Human interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human interferon (given once daily for seven days)
Study: 22094836
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 μg 1,25‐dihydroxy cholecalciferol per capsule, 2 capsules per day)
Study: 22299644
Drug: 2000 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 µg BDP solution with 5 g oral charcoal (OralC)
Study: 22299644
Drug: 2000 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 µg BDP solution without oral charcoal (Oral)
Study: 22299644
Drug: 10,100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,100 µg inhalations from Qvar(®) pMDI (Qvar)
Study: 22299644
Drug: eight 250
Normalized name: Novoeight 250units Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: eight 250 µg inhalations from Clenil(®) pMDI (Clenil)
Study: 14630756
Drug: Steroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and acetic acid ear drops
Study: 14630756
Drug: Steroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and antibiotic ear drops
Study: 9797832
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) (10 mg/kg)
Study: 7653663
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion (0.4 micrograms.kg‐1.min‐1)
Study: 799974
Drug: Metoprolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (150 and 300 mg/day)
Study: 799974
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 and 240 mg/day)
Study: 799974
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 and 6 tablets per day)
Study: 28887592
Drug: Antidepressant DTCA
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant DTCA with portrayals of discrimination, cognitive separation, and stereotyping (DCSS)
Study: 27179825
Drug: EECP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EECP treatment (35 1‐h sessions)
Study: 25409886
Drug: Intensive psychological
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive psychological therapy alone
Study: 20711429
Drug: ZK 200775
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 200775 at 0.03 mg/kg/h
Study: 20711429
Drug: ZK 200775
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 200775 at 0.75 mg/kg/h
Study: 20711429
Drug: ZK 200775
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 200775 (both doses)
Study: 2496240
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy program for urinary incontinence (13 weeks)
Study: 610325
Drug: Combination induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination induction therapy with vincristine and prednisolone
Study: 610325
Drug: Cyclic therapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic therapy (721-A) with intermittent high-dose infusion of methotrexate
Study: 610325
Drug: Cyclic intrathecal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic intrathecal medication during remission or combination therapy with 2,400 rads cranial irradiation plus intrathecal medication
Study: 610325
Drug: Patients maintained
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients maintained without further chemotherapy after complete remission
Study: 610325
Drug: Patients taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients taken off therapy
Study: 31781755
Drug: Filgotinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib, a selective JAK1 inhibitor
Study: 31781755
Drug: Tofacitinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib, a pan‐JAK inhibitor
Study: 25952317
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily followed by sunitinib 50mg once daily (4 wk on, 2 wk off)
Study: 25952317
Drug: Sunitinib 50mg
Normalized name: sunitinib 50 MG
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50mg once daily (4 wk on, 2 wk off) followed by sorafenib 400mg twice daily
Study: 22092152
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (pelvic floor muscle exercises, urge suppression techniques, delayed voiding)
Study: 22092152
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (individually titrated, extended‐release oxybutynin, 5‐30 mg/d)
Study: 19673667
Drug: torasemide-PR (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: torasemide-PR (10-40 mg daily)
Study: 19673667
Drug: furosemide (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: furosemide (40-160 mg daily)
Study: 10966703
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (in patients aged 2 years or younger with grade IV VUR, bilateral VUR, or renal scars)
Study: 10966703
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (in patients with unilateral renal scarring or thin parenchyma)
Study: 10966703
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (in patients with bilateral renal scarring)
Study: 8990731
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (three 15-minute massages daily for 10 days)
Study: 1731418
Drug: Nimodipine 120
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 120 mg daily
Study: 31363811
Drug: Subfascial implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial implant placement
Study: 31363811
Drug: Subglandular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subglandular implant placement
Study: 29465751
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus surgery (CS) group
Study: 25231089
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: lansoprazole 30 mg bid, amoxicillin 1.0 g tid, rifabutin 150 mg bid for 7 days
Study: 25231089
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: lansoprazole 60 mg bid, amoxicillin 1.0 g tid, rifabutin 150 mg bid for 7 days
Study: 22313068
Drug: Control (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (blood cardioplegia without L-arginine)
Study: 19837545
Drug: Moderate lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate lipid-lowering therapy with low-dose atorvastatin (10 mg-20 mg)
Study: 19837545
Drug: Aggressive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid-lowering therapy with high-dose atorvastatin (80 mg)
Study: 16533867
Drug: Guaraná extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaraná extract 37.5 mg
Study: 16533867
Drug: Guaraná extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaraná extract 75 mg
Study: 16533867
Drug: Guaraná extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaraná extract 150 mg
Study: 16533867
Drug: Guaraná extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaraná extract 300 mg
Study: 16239201
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at a dose equal to the mean of their total daily CSII basal insulin dose (group 1:1)
Study: 16239201
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at a dose of 1.2 times the mean of their total daily CSII basal insulin dose (group 1:1.2)
Study: 12204788
Drug: 4% Dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Dextrin sulphate (DS) gel applied topically to the penis once per day for 14 consecutive days, left on for a minimum of 6 hours.
Study: 12204788
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied topically to the penis once per day for 14 consecutive days, left on for a minimum of 6 hours.
Study: 10567865
Drug: 0.1% indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% indomethacin solution
Study: 1924667
Drug: Haloperidol (neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (neuroleptic threshold doses)
Study: 6356924
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2 gm intramuscularly over 12 hours)
Study: 26188849
Drug: Ethanol locks
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol locks (1.5 or 3 ml 70%)
Study: 26188849
Drug: Heparin locks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin locks (1.5 or 3 ml 100 IU/ml)
Study: 24095901
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for Panic Disorder, 11 sessions
Study: 16680475
Drug: Saline-adrenaline-lidocaine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline-adrenaline-lidocaine solution injected (40 ml)
Study: 11063905
Drug: Kliogest (norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kliogest (norethisterone acetate 1 mg and oestradiol valerate 2 mg)
Study: 2856601
Drug: Amikacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (500 mg every 12 hours) and Ticarcillin (3 gm every six or eight hours)
Study: 25754510
Drug: Proaftol spray,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proaftol spray, applied as two sprayings on the site of the aphthae 3-4 times a day.
Study: 25754510
Drug: Placebo spray,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray, applied as two sprayings on the site of the aphthae 3-4 times a day.
Study: 25754510
Drug: Proaftol spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proaftol spray
Study: 10945311
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg administered simultaneously with ketoconazole 200 mg
Study: 10945311
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg administered 12 hours before ketoconazole 200 mg
Study: 10945311
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg administered once daily in the morning
Study: 9493660
Drug: Control: ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: ambient temperature (tamb) = 25 degrees C, rectal temperature change (delta tre) = 0 degrees C
Study: 8399251
Drug: Previous dental
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous dental visits and procedures, oral hygiene instruction, and x‐rays
Study: 3091801
Drug: Cefadroxil 30
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil 30 mg/kg once daily for 10 days
Study: 3091801
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg three times daily for 10 days
Study: 3091801
Drug: Cefadroxil 30
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil 30 mg/kg once daily
Study: 3091801
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg three times daily
Study: 31307747
Drug: Alfentanil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (15 μg/kg)
Study: 31307747
Drug: Fentanyl (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.5 μg/kg)
Study: 31307747
Drug: Remifentanil (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1.5 μg/kg)
Study: 29058822
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg every 4 weeks for 28 weeks
Study: 22203120
Drug: IT injection
Normalized name: chymopapain 4 unit INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection without any previous anesthesia
Study: 22203120
Drug: IT injection
Normalized name: chymopapain 4 unit INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection with EMLA cream
Study: 22203120
Drug: IT injection
Normalized name: chymopapain 4 unit INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection with subcutaneous lidocaine 1%
Study: 22203120
Drug: IT injection
Normalized name: chymopapain 4 unit INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection with methylprednisolone
Study: 22203120
Drug: IT injection
Normalized name: chymopapain 4 unit INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection with gentamicin
Study: 21029874
Drug: Augmentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation of ST-segment elevation ≥0.05 mV in V(1) to V(3) leads during early recovery (1 to 4 min)
Study: 21029874
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation of ST-segment elevation
Study: 12173947
Drug: Low-dose creatine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose creatine supplementation
Study: 12173947
Drug: High-dose creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose creatine supplementation
Study: 11093435
Drug: Intramuscular gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gold sodium thiomalate (GSTM)
Study: 11093435
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with double dose of RA linked alleles
Study: 9098861
Drug: Insulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (30 microU/mL)
Study: 9098861
Drug: Insulin receptor
Normalized name: Insulin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin receptor mRNA expression
Study: 25966916
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control vaccines
Study: 19349552
Drug: Oral sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sorafenib 400 mg twice daily on days 2 to 19 plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Study: 19349552
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Study: 11142539
Drug: MBT (M
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBT (M plus behavioral coping skills therapy)
Study: 9272298
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion for five consecutive days (7-hour infusion)
Study: 9272298
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion for one day
Study: 7525359
Drug: Oral danazol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral danazol, 50 mg/d for 9 months (group I, n = 21)
Study: 7525359
Drug: Leuprolide depot
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide depot for 3 months followed by oral danazol, 50 mg/d for 6 months (group II, n = 21)
Study: 21986980
Drug: Intravenous physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous physiological saline (control group)
Study: 18728172
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at 33 microg/kg.d
Study: 18728172
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at 67 microg/kg.d
Study: 14631268
Drug: Continuous hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous hormone therapy with rivastigmine (n=59)
Study: 8087522
Drug: Chemotherapy (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (doxorubicin, etoposide, cyclophosphamide, plus methotrexate or cisplatin) and thoracic radiotherapy (total dose of 45, 55, 65 and 61 Gy)
Study: 8087522
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and thoracic radiotherapy
Study: 2669155
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg plus triamterene (50 mg)
Study: 782970
Drug: Spray device
Normalized name: AMPUL WITH PUMP SPRAY DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray device 1
Study: 782970
Drug: Spray device
Normalized name: AMPUL WITH PUMP SPRAY DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray device 2
Study: 782970
Drug: Spray device
Normalized name: AMPUL WITH PUMP SPRAY DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray device 3
Study: 782970
Drug: Analgesics (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics (for volunteers with fourfold or greater antibody response)
Study: 782970
Drug: No analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesics (for volunteers with no serological response)